Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Great but need figures/forecasts - means nothing when assessing value.
I thought the presentation was poor and unambitious - peeps want big deals not 100k here and there - and they have one Glyco - which was not mentioned, forecast market penetration ignore - delays not explained [3 years] - why ?
A better share price means they can raise with min dilution and be more agressive.
This is a PDS margin play atm and will be until they get some balls.
Sofant? Its brilliant but silience - even a kid could sell the co better.
Finally.
A new website and company update from ProAxis on it's way.
7 products on the market.
ProteaseTag Active Neutrophil Elastase Immunoassay (CE Marked)
ProteaseTag Active Proteinase 3 Immunoassay (CE Marked)
ProteaseTag Active Cathepsin G Immunoassay (Research-Use Only)
NEATstik (lateral flow test for active Neutrophil Elastase; CE Marked)
K-POSTn immunoassay (In-licensed from University of Geneva; CE Marked)
Covid-19 serology assay (In-licensed from AstraZeneca; CE Marked)
NE Premium (High-sensitivity Neutrophil Elastase assay; CE Marked)
SageTech Medical
@SageTechMedical
·
Jan 30
A fantastic month for SageTech Medical - The official UK launch of our solution for the capture and #recycling of waste volatile #anaesthetic agents and the unveiling of our brand new machine has been a huge success! Thank you to everyone who has supported our journey so far!
Also a great interview with the lead at the RD@E Exeter where it has been tested for the last 2 years.
NSCI only have a 1% holding but still looks like a great product for an important illness.
https://www.verywellhealth.com/new-screening-test-for-sepsis-7097947
I think we all agree there is no escaping the fact that NSCI is totally off radar to most investors.
PDSB + cash again equals our market cap, leaving the other £25/30M of assets valued at zero.
The boss and his mate own 50% so you would assume they are as pvssed off as the rest of us?
A number of their companies are progressing to sales and expansion, Sagetech/QBot/Proaxis for a start, so worth more than last years valuation?
Frustrating doesn't come close.
I assume not !!
Was it any good?
Let's see if tonight wakes anyone up?
This share is so excruciatingly painful to watch let alone be invested. They have alot strings to their bow but it's taking forever to shoot those arrows on the bull.
Seriously undervalued however the market obviously thinks different based on current juncture.
"can sell"
Yep. But it show they sell. Atm they are good at buying !!
Yes it feels like many investors feel the same, hence the slow grind lower in price as people get bored/tired of waiting and sell out.
There is a real lack of a wider pool of investors who want to get involved, everyone who reads this board will have all looked into the portfolio of companies and seen something they like, and see real value (probably way above the current share price) but you need new eyes, new investors, new money to come and see the same and buy it. It's just not on people's radar at all at the moment.
The big move in PDSB shined a bit of a light on this stock, but if the market priced a value of the rest of the entire portfolio of NSCI companies of only a few £million at that point, it also says a lot about the (lack of) appetite to invest in this company. Growth stocks are not in favour right now, this will not always be the case. I feel to see some semblance of fair value you will need to wait 12+ months. I'd love to see a liquidity event or some real buzz in one of the companies, but if they did sell a chunk of something the money wouldn't be distributed, it would be reinvested in something else - but ask yourself would you want it any other way?
I'm patient but even I am getting bored.
I like their investments alot but we need a decent liquidity event soon otherwise they will need more cash - or stop investing.
Fingers crossed.
some one aint happy
7hrs ago.
Excellent Sagetech interview on Proactive.
Our CEO, Iain Menneer, talks to
@proactive_UK
's Thomas Warner about the #environmental damage caused by waste volatile #anaesthetic agents and the #innovative solution that SageTech Medical has developed to capture, recover and #recycle these agents.
Anyone in London going to the NSCI Proactive presentation next Thursday 6pm?
The opportunity to work with Eon on the Karbon Homes and other similar projects represents a significant milestone in Q-Bot’s growth. Eon are involved in roughly 20% of all UK Housing Retrofit Projects, and our close collaboration, which has developed through our early Energy Company Obligation (ECO) funding relationship show an exciting trajectory for our innovative underfloor insulation solution. Leigh Fairbrother, Q-Bot Head of Commercial
Q-Bot appointed by energy solutions provider E.ON to install measures to improve the efficiency of Otterburn homes
12 January 2023
Q-Bot has recently been appointed by energy solutions provider E.ON to install its robotic underfloor insulation in 34 properties in Otterburn in the North of England.
The homes are managed by Karbon Homes, which aims to get these properties close to net zero by installing several energy efficiency measures funded through the Social Housing Decarbonisation Fund wave 1.
Formed in 2017, Karbon Homes is a housing association in the North East of England and Yorkshire, managing almost 30,000 homes. They are focused on delivering good quality homes, excellent service to their customers, and creating a sustainable and friendly environment for their local communities.
Karbon Homes aims to drive the path to net zero homes by installing multiple energy efficiency measures. This will involve ensuring appropriate insulation coverage in lofts and increasing the thickness where required, installing external or cavity wall insulation, solar panels which will generate electricity for customers to use for free, and finally Q-Bot’s underfloor insulation.
Anthony Bell, Karbon’s Assistant Director of Asset and Regeneration said: “With the cost of energy rising fast, our work to improve the efficiency of our homes has never been more important. This significant investment, made possible thanks to support from our local authority partners, will reduce the energy demand from these 90 homes and in turn reduce carbon emissions.”
E.ON is the managing agent on behalf of Karbon Homes, acting as the Principal Contractor. E.ON is an energy provider of energy efficiency measures to social housing associations, local authorities, and private residential customers. The retrofit measures are usually financed through government funding such as the Local Authority Delivery Scheme, Social Housing Decarbonisation Fund and Energy Company Obligation. E.ON plays a key role in the retrofit sector, delivering 11 other similar upgrade schemes across the country.
Dave Newitt, Director of E.ON’s Energy Installation Services division, said: “We work with local authorities and housing associations across the country to improve the energy efficiency and sustainability of people’s homes and we’re delighted to be working with Q-Bot and Karbon Homes to improve the energy efficiency of homes across the Otterburn region.
By working with organisations such as the Karbon Homes, we’re able to utilise existing funding programmes through our Energy Company Obligation, to ensure residents can become more sustainable and benefit from lower energy bills and we can work together to support the UK’s net zero ambition.”
Q-Bot provides a unique method of installing underfloor insulation, fully recognised, and leveraged in the housing sector. Operating from its headquarters in London and with operational bases in New
In Person Event - Thursday 26th January 2023
You are warmly invited to participate in the Proactive ONE2ONE investor forum which is taking place on Thursday 26th January from 17:45 onwards at The Chesterfield Mayfair Hotel (35 Charles Street, Mayfair, London, W1J 5EB).
REGISTER
Presenting companies:
Mosman Oil and Gas LTD (LON:MSMN)
Roquefort Therapeutics PLC (LON:ROQ) is a biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.
The company's portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines.
Lavras Gold Corp (CVE:LGC)
NetScientific PLC (LON:1SN) is an investment and commercialisation group with an international portfolio of innovative life science, sustainability and technology companies.
The company identifies, invests in, and builds high growth companies in the UK and internationally.
Canada Silver Works (CVE:CCW)
Scirocco Energy PLC (LON:SCIR) is an AIM investing company targeting attractive production and development opportunities within the European transition energy market.
Yellow Cake plc (LON:YCA)
CentralNic Group PLC (LON:CNIC) is the developer and operator of software platforms providing web presence services to customers in almost every country in the world.
Headquartered in London, the company is a leading provider of tools required to create websites, use email, and secure business online.
Twitter
LinkedIn
YouTube
Facebook
Instagram
This event is suitable for sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists. The event is not suitable for people pursuing commercial opportunities Click here to unsubscribe.
Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, with Company Registration number 05639690. Group VAT registration number 872070825
Diepenbeek, Belgium, January 13th, 2023 – Fox BIOSYSTEMS announces today that
they successfully closed on their funding round, raising €5.8M in new capital. Investors in
this round are Heran Partners, LRM, The Gemma Frisius Fund, KU Leuven, and
NetScientific.
FOX BIOSYSTEMS has developed an innovative Surface Plasmon Resonance (SPR)
technology using optical sensors. Their product, the White FOx, combines a microfluidicsfree
dip-in protocol for fast and user friendly SPR sensing. The unique approach of the
White FOx eliminates the risk of clogging and cross-contamination when using complex
samples such as lysates, whole blood or large particles. The sensor probes are available
with several generic surface chemistries and can be switched easily to allow the detection
of different target molecules, including antibodies, nanobodies, microvesicles, phages and
large particles, all with a single lab device.
A wide range of applications make the White FOx the ideal option for any life science or
biopharmaceutical research lab. Kinetic affinity analysis, label free biomolecule
quantification and fast specific and ultra-sensitive sandwich assays are all possible and
uniquely facilitate analysis of complex unpurified samples.
The additional raised capital will be used to scale up the company’s operations, accelerate
the development of new application areas, and to boost the commercialization of this
unique system.
Thomas van Elzakker, CEO of FOx BIOSYSTEMS: “We are very happy with the strong
support of our investors for our highly motivated team in realizing our vision for FOx
BIOSYSTEMS. They are confidently investing in our fast commercial growth today, while
also enabling us to deliver on our exciting innovation roadmap for tomorrow. The White
FOx system offers a solution to many of today’s analysis challenges, and it will continue
to be key in revealing new data and helping scientists to reach their goals more quickly.”
Katleen Vandersmissen, PhD, Chair of FOx BIOSYSTEMS and Managing Partner of HERAN
Partners: “With HERAN we try to spot those technologies and teams that can make a
difference and positive impact within the domain of Life Sciences. We believe that FOx,
now strongly backed by this financing round and the recent EIC grant, is up for success
based on their innovative take and ease of use on complex samples.”
About FOx Biosystems
FOx BIOSYSTEMS is a Belgian company with a mission to revolutionize the life sciences
and pharmacological research market with innovative real-time, label-free analysis
products. The basis of their success is a novel fiber-optic-based SPR biosensor which
enables users to generate high-quality, cost-effective biomolecular data fast, and over a
wide range of applications.
For more information visit www.foxbiosystems.com
Contact:
Mr. Kris Ver Donck, VP Marketing & Applications
info@foxbiosystems.com
About Heran Partners
Heran Partners is a Belgian-based MedTech an
Have to say it is quite unbelievable that ProAxis still haven't updated their website with the 3/4 new products.
There was mention of a new site but shocking that with all the new hires and expansion they miss the basics.
Looks like ProAxis is finally ready to showcase itself.
JPMorgan Healthcare is the place to be and you might notice they now have offices in Rockville USA.
Looking forward to the annual update (last year 6th Jan)
ProAxsis
@ProAxsis
·
3h
Please email info@proaxsis.com to schedule a meeting at JPM, or for any other further information.
#healthcare #JPMconference #proteases #biomarkers #assaydevelopment #invitrodiagnostics #diseasemanagement #respiratorydisease #bonehealth
ProAxsis
@ProAxsis
·
Dec 14, 2022
Christmas is approaching so place your orders now for a timely delivery for Q1 or even sooner.
2022 saw our company grow with Head Office doubling in size and the launch of new key products.
We will continue to build on this with all our partners, current and new in 2023!
Some nice buys
This a great little company fingers in pies
Care to enlighten us?